Antithrombotic Therapy After Coronary Stenting in Patients With Nonvalvular Atrial Fibrillation

Canadian Journal of Cardiology

Volumn 29, Issue 2, 2013, Pages 213-218

  Ho, Kay W ^a,b   Ivanov, Joan ^a,c   Freixa, Xavier ^a   Overgaard, Christopher B ^a   Osten, Mark D ^a   Ing, Douglas ^a   Horlick, Eric ^a   Mackie, Karen ^a   Seidelin, Peter H ^a   Džavík, Vladimír ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; IRBESARTAN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY STENT; DEEP VEIN THROMBOSIS; DISEASE CONTROL; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; SCORING SYSTEM; TRANSIENT ISCHEMIC ATTACK;

AGED; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MYOCARDIAL ISCHEMIA; ONTARIO; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STENTS; STROKE;

EID: 84872683152     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.08.008     Document Type: Article

References (27)

1. Al Khdair D., Alshengeiti L., Elbarouni B., et al. Management and outcome of acute coronary syndrome patients in relation to prior history of atrial fibrillation. Can J Cardiol 2012, 28:443-449.
2. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
3. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
4. Go A.S., Hylek E.M., Chang Y., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 2003, 290:2685-2692.
5. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
6. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
7. Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912.
8. King S.B., Smith S.C., Hirshfeld J.W., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008, 51:172-209.
9. Bell A.D., Roussin A., Cartier R., et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011, 27(Suppl A):S1-S59.
10. Konstantino Y., Iakobishvili Z., Porter A., et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006, 105:80-85.
11. Orford J.L., Fasseas P., Melby S., et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004, 147:463-467.
12. Mattichak S.J., Reed P.S., Gallagher M.J., Boura J.A., O'Neill W.W., Kahn J.K. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 2005, 18:163-166.
13. Porter A., Konstantino Y., Iakobishvili Z., Shachar L., Battler A., Hasdai D. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2006, 68:56-61.
14. Khurram Z., Chou E., Minutello R., et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006, 18:162-164.
15. DeEugenio D., Kolman L., DeCaro M., et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007, 27:691-696.
16. Karjalainen P.P., Porela P., Ylitalo A., et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007, 28:726-732.
17. Nguyen M.C., Lim Y.L., Walton A., et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?. Eur Heart J 2007, 28:1717-1722.
18. Ruiz-Nodar J.M., Marin F., Hurtado J.A., et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008, 51:818-825.
19. Rogacka R., Chieffo A., Michev I., et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv 2008, 1:56-61.
20. Gao F., Zhou Y.J., Wang Z.J., et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010, 74:701-708.
21. Manzano-Fernandez S., Pastor F.J., Marin F., et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008, 134:559-567.
22. Halbfass P., Janko S., Dorwarth U., Riess G., Antoni D., Hoffmann E. Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience. Europace 2009, 11:957-960.
23. Connolly S.J., Eikelboom J.W., Ng J., et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011, 155:579-586.
24. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991, 84:527-539. Stroke Prevention in Atrial Fibrillation Investigators.
25. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
26. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
27. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.